Prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) employs radiolabeled molecules that bind to PSMA - a transmembrane glutamate carboxypeptidase highly expressed on prostate cancer cells - to deliver potent radiation doses directly to malignant cells. This evidence concerns the gene FOLH1 and prostate cancer.